Screener
Dyne Therapeutics, Inc. DYN Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseOther.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (125,276) | (122,372) |
| Other income (expense): | ||
| Interest income | 8,757 | 7,100 |
| Interest expense | (4,202) | — |
| Other expense, net | (133) | (89) |
| Total other income, net | 4,422 | 7,011 |
| Net loss | $(120,854) | $(115,361) |
| Net loss per share—basic and diluted | $(0.73) | $(1.05) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s interest expense?
- Dyne Therapeutics, Inc. (DYN) reported interest expense of $4.2M in Q1 2026.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Dyne Therapeutics, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude